Search the Newsreel

Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Sells 75,834 Shares of Stock

Rhythm Pharmaceuticals EVP, Jennifer Lee, sells $8.9m in stock

Jennifer Lee, EVP of Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM), sold approximately $8.9 million worth of common stock after exercising options for about $997,036. The sale was executed under a Rule 10b5-1 trading plan as the stock trades near its 52-week high and is considered overvalued …

Rhythm Pharmaceuticals (RYTM) EVP exercises 56,601 options and sells 75,834 shares

Jennifer Kayden Lee, EVP of Rhythm Pharmaceuticals (RYTM), exercised 56,601 stock options at prices of $24.29 and $6.80, and subsequently sold 75,834 common shares at $117.3818 per share. These transactions, valued at approximately $8.90 million gross proceeds from sales and $997K in exercise costs, …

Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript

How Investors Are Reacting To Rhythm Pharmaceuticals (RYTM) UK Orphan Expansion For IMCIVREE In Hypothalamic Obesity

Rhythm Pharmaceuticals received expanded UK MHRA authorization and orphan drug designation for IMCIVREE to treat hypothalamic obesity, broadening its market in the UK. While this strengthens the rare-disease thesis for the drug, the company continues to operate at a significant loss, underscoring ongoing funding …

RYTM (NASDAQ: RYTM) investor plans sale of 5,079 shares worth $597K

An investor in Rhythm Pharmaceuticals (NASDAQ: RYTM) has filed a notice to sell 5,079 shares of common stock, valued at $597,290.40. The sale is planned through Morgan Stanley Smith Barney LLC on or after August 13, 2026, on NASDAQ. These shares originate from stock …

RYTM (RYTM) insider plans Form 144 sale of option and RSU shares

An insider at Rhythm Pharmaceuticals (RYTM) has filed a Form 144 indicating a proposed sale of 75,834 common shares through Morgan Stanley Smith Barney LLC. This total includes 56,601 shares from stock option exercises dated August 13, 2026, and 19,233 shares from Restricted Stock …

Rhythm Pharmaceuticals (RYTM) plans 57,000-share stock sale via broker

Rhythm Pharmaceuticals (RYTM) has announced a planned sale of 57,000 shares of its common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The total aggregate market value of these shares is $6,432,165.00, with the sale scheduled for August 12, 2026. This transaction …

Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?

Rhythm Pharmaceuticals (NASDAQ: RYTM) stock is trading higher due to the UK's expanded marketing authorization for its drug, Imcivree (setmelanotide). The approval now includes treatment for obesity and hunger control in adults and children with acquired hypothalamic obesity. Analysts have reiterated Buy ratings and …

Rhythm Pharmaceuticals (RYTM) insider outlines 10b5-1 stock sale plan in Form 144

A Rhythm Pharmaceuticals insider, Pamela Cramer, has filed a Form 144 detailing planned sales of company common stock through a 10b5-1 plan via Morgan Stanley Smith Barney LLC. The filing includes shares from stock option exercises and restricted stock units, alongside a previous sale …

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

Rhythm Pharmaceuticals, Inc. -- MHRA grants authorization for patients 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment -- BOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused …

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Rhythm Pharmaceuticals (NASDAQ:RYTM) has received a "Moderate Buy" consensus recommendation from brokerages, with 15 out of 18 analysts rating the stock as a buy. The average 12-month price target is $142.44, exceeding the current share price of $115.48. The company reported strong quarterly revenue …

RHYTHM PHARMACEUTICALS, INC. SEC Filing (Aug 10, 2026)

This article details an SEC Form 144 filing by RHYTHM PHARMACEUTICALS, INC. (RYTM) on August 10, 2026. The filing indicates a proposed sale of 3,520 common shares with an aggregate market value of $407,017.60, acquired through the exercise of stock options on the same …

RYTM - High-Growth Emerging Commercial Stage Biotech

Rhythm Pharmaceuticals (RYTM) is presented as a high-growth commercial-stage biotech company focused on orphan neuroendocrine disorders, particularly those related to MC4R pathway dysfunction (genetic obesity). The article highlights the company's strong Q2 2026 results for IMCIVREE, with better-than-expected patient uptake and international growth, along …

Rhythm Pharmaceuticals (RYTM) Reports Promising RM 718 Data, Is The Upside Already Priced In?

How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Q2 Results And Early RM-718 Obesity Data

Rhythm Pharmaceuticals reported stronger Q2 2026 revenues for IMCIVREE and promising early Phase 2 data for its new drug RM-718 for acquired hypothalamic obesity. The article discusses how these developments may refine the company's investment narrative, which currently balances growth from its rare-disease franchise …

Rhythm Pharmaceuticals (RYTM) Stock Rises As HO Demand Meets Loss Pressure

Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $160.00

Citizens JMP raised its price target for Rhythm Pharmaceuticals (NASDAQ:RYTM) to $160.00 from $155.00, maintaining a "market outperform" rating and suggesting a 47.56% upside. The company reported strong Q3 revenue of $71.25 million, exceeding estimates, and beat EPS expectations. Analyst sentiment remains largely positive …

Rhythm Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:RYTM) 2026-08-05

Rhythm Pharmaceuticals, Inc. published its Q2 2026 earnings call presentation, detailing its financial results. The company reported an EPS of -$0.73, beating estimates by $0.10, and revenue of $71.26M, a 46.91% year-over-year increase, exceeding expectations by $3.60M. This report was issued in conjunction with …

Citigroup Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

RBC Adjusts Price Target on Rhythm Pharmaceuticals to $155 From $141, Maintains Outperform Rating

RBC Capital has increased its price target for Rhythm Pharmaceuticals (RYTM) to $155 from $141, while reiterating an Outperform rating on the stock. This adjustment follows Rhythm Pharmaceuticals' Q2 2026 earnings call and other recent news, including promising data for its drug in brain …

Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call

Rhythm Pharmaceuticals reported strong Q2 2026 results with global net product sales of IMCIVREE at $71.3 million, a 19% sequential increase. The company highlighted a successful U.S. launch of IMCIVREE for acquired hypothalamic obesity, receiving over 400 start forms in 14 weeks. Promising preliminary …

RHYTHM PHARMACEUTICALS, INC. 2026: Revenue $71.26M, EPS ($0.73) — 10-Q Summary

RHYTHM PHARMACEUTICALS, INC. (RYTM) reported its 2026 results, showing revenue of $71.26 million, a 46.9% increase from the prior year. Despite the revenue growth, the company posted a net loss of $50.36 million and a diluted EPS of ($0.73). The growth was primarily driven …

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Rhythm Pharmaceuticals, Inc. announced that its Chairman, President and Chief Executive Officer, David Meeker, M.D., and Chief Financial Officer, Hunter Smith, will participate in fireside chats at three upcoming investor conferences in August and September 2026. These presentations will be webcasted and available on …

Rhythm Pharmaceuticals (NASDAQ:RYTM) Issues Quarterly Earnings Results

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals (RYTM) reported a Q2 loss of $0.73 per share, exceeding the Zacks Consensus Estimate of a $0.81 loss by 9.88%. The company also surpassed revenue estimates, posting $71.26 million against an expectation of $67.12 million. Despite outperforming earnings expectations in three of …

Earnings Flash (RYTM) Rhythm Pharmaceuticals, Inc. Reports Q2 Revenue $71.3M, vs. FactSet Est of $67.7M

Rhythm Pharmaceuticals, Inc. reported its Q2 2026 revenue at $71.3 million, surpassing the FactSet estimate of $67.7 million. The company's lead asset, IMCIVREE, is an MC4R agonist approved for treating hyperphagia and severe obesity in various genetic and acquired conditions. Rhythm Pharmaceuticals is also …

Rhythm Pharmaceuticals 2Q Rev $71.3M >RYTM

Rhythm Pharmaceuticals reported its second-quarter revenue of $71.3 million. This brief report provides a key financial update for the company.

Rhythm Pharmaceuticals GAAP EPS of -$0.73 beats by $0.09, revenue of $71.26M beats by $3.6M

* Rhythm Pharmaceuticals press release [https://seekingalpha.com/pr/20605381-rhythm-pharmaceuticals-reports-second-quarter-2026-financial-results-and-business-update] (RYTM [https://seekingalpha.com/symbol/RYTM]): Q2 GAAP EPS of -$0.73 beats by $0.09. * Revenue of $71.26M (+46.9% Y/Y) beats by $3.6M. * Net product revenues from global sales of IMCIVREE were $71.3 million for the second quarter of 2026, as …

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Rhythm Pharmaceuticals reported strong second-quarter 2026 financial results, with global IMCIVREE sales reaching $71.3 million, a 19% sequential increase. The company highlighted a successful U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO), with over 400 patient start forms, and positive clinical data for …

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals announced positive preliminary data from its Phase 2 trial of RM-718, an investigational once-weekly MC4R agonist, for acquired hypothalamic obesity (HO). The study showed an 11.6% mean reduction in BMI from baseline at Week 16, consistent with previous treatments like setmelanotide and …

After FDA approval, Rhythm's IMCIVREE logs more than 400 U.S. start forms

Rhythm Pharmaceuticals announced strong Q2 2026 financial results, with net product revenue from global IMCIVREE sales reaching $71.3 million, a 19% sequential increase. The growth was largely driven by the U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO), which generated over 400 patient …

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Look at Strong Analyst Ratings and Significant Growth Potential

Rhythm Pharmaceuticals (RYTM) is gaining investor attention due to its promising drug pipeline for rare neuroendocrine diseases and strong analyst endorsements. Despite current unprofitability and a slight stock price dip, its significant revenue growth and high average target price suggest substantial growth potential. Investors …